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ABSTRACT
Background: There is a paucity of data on extraintestinal manifestations
(EIM) and their treatment in pediatric patients with inflammatory bowel
disease (IBD).
Methods: Since 2008, the Pediatric Swiss IBD Cohort Study has collected
data on the pediatric IBD population in Switzerland. Data on 329 patients
were analyzed retrospectively.
Results: A total of 55 patients (16.7%) experienced 1–4 EIM (39 Crohn
disease, 12 ulcerative colitis, and 4 IBD-unclassified patients). At IBD onset,
presence of EIM was more frequent than in the adult population (8.5% vs 5.0%,
P¼ 0.014). EIM were more frequent in Crohn disease when compared to
ulcerative colitis/IBD-unclassified (22.5% vs 10.3%, P¼ 0.003). The most
prevalent EIM were peripheral arthritis (26/329, 7.9%) and aphthous stomatitis
(24/329, 7.3%). Approximately 27.6% of all EIM appeared before IBD
diagnosis. Median time between IBD diagnosis and occurrence of first EIM
was 1 month (37.5–149.0). Thirty-one of the 55 patients (56.4%) were treated
with 1 or more anti–tumor necrosis factor (TNF) agents. IBD patients with EIM
were more likely to be treated with anti-TNF compared to those without (56.4%
vs 35.0%,P¼ 0.003). Response rates to anti-TNF depended on underlying EIM
and were best for peripheral arthritis (61.5%) and uveitis (66.7%).
Conclusions: In a cohort of pediatric patients with IBD, EIM were
frequently encountered. In up to 30%, EIM appeared before IBD
diagnosis. Knowledge of these findings may translate into an increased
awareness of underlying IBD, thereby decreasing diagnostic delay. Anti-
TNF for the treatment of certain EIM is effective, although a substantial
proportion of new EIM may present despite ongoing anti-TNF therapy.
Key Words: anti– tumor necrosis factor, arthritis, extraintestinal
manifestations, inflammatory bowel disease, uveitis
(JPGN 2017;65: 200–206) I nflammatory bowel diseases (IBDs) are chronic inflammatorydisorders of the gastrointestinal tract and can be classified into
the 2 main subtypes Crohn disease (CD) and ulcerative colitis (UC)
What Is Known
 Extraintestinal manifestations are frequently observed
in adult patients with inflammatory bowel disease.
 Little is known about extraintestinal manifestation in
the pediatric inflammatory bowel disease popu-
lation.
What Is New
 Extraintestinal manifestations are common in
pediatric patients with inflammatory bowel disease.
 Epidemiology and presentation of extraintestinal
manifestation seem to be similar in the pediatric
and adult inflammatory bowel disease population.
 In up to 30% of those patients presenting with
extraintestinal manifestation, extraintestinal manifes-
tation appear before inflammatory bowel
disease diagnosis.
 Type of extraintestinal manifestation may affect the
responses to anti–tumor necrosis factor. Best rates
were seen for peripheral arthritis and uveitis.
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(1). As IBDs are systemic diseases, which can involve multiple
organ systems, extraintestinal manifestations (EIM) are frequently
observed affecting up to 50% of the adult IBD population (2–6). In
a non-negligible proportion, EIM appear even before IBD diagnosis
is established (7). Although some reviews broaden the concept of
EIM to non–IBD-specific autoimmune disorders such as thyroid
disease or vitiligo and IBD-related complications such as osteo-
pathy or nephrolithiasis, the typical EIM involve the following 4
organs: skin (erythema nodosum [EN], pyoderma gangrenosum
[PG], psoriasis, aphthous stomatitis), joints (peripheral arthritis,
axial arthropathy), biliary tract (primary sclerosing cholangitis
[PSC]), and eyes (uveitis) (7). Most of EIM parallel intestinal
disease activity (8–12), are more common in CD than in UC,
and are more frequently observed with longer IBD duration (13). In
addition, up to one quarter presents with more than 1 EIM (8).
Morbidity and mortality are considerably affected (14,15).
Although pathogenesis remains mostly elusive, intestinal and extra-
intestinal IBDs seem to share tumor necrosis factor (TNF)-depen-
dent mechanisms (16) and several studies and case reports were able
to demonstrate beneficial effect of anti-TNF treatments (17–23).
EIM (such as arthritis and paradoxical psoriasiform reactions) can,
however, also resemble adverse effects of anti-TNF therapy (24).
Although knowledge of prevalence, appearance, and
possible treatment options for EIM in adults is increasing, it is
still limited in the pediatric IBD population. Recent studies have
shown higher rates of EIM at IBD onset compared with adults with
peripheral arthritis and aphthous stomatitis being the most prevalent
(25,26). To our knowledge, so far no study has addressed the
chronological order of EIM appearance in respect to IBD diagnosis
or the influence of anti-TNF treatment on the evolution and
development of EIM in a pediatric IBD cohort. Given this paucity
of data, we aimed to assess the frequency and type of EIM,
chronological order of appearance of EIM, and the use of and
response to anti-TNF treatment in the Pediatric Swiss IBD Cohort
Study (PSIBDCS).
METHODS
Patients
The PSIBDCS is a nationwide substudy of the Swiss IBD
Cohort Study (SIBDCS) including all regions of Switzerland (27).
Enrollment started in 2008. The SIBDCS and its substudy are
supported by the Swiss National Science Foundation and are
approved by the local ethics committees of the participating centers.
Patients are included in the PSIBDCS if they are 18 years or
younger. Additional inclusion criteria and regular assessment
scheme (baseline and annual follow-up questionnaires) have been
discussed elsewhere (28). Patients were recruited at University
Hospitals, community hospitals, and large private practices
throughout Switzerland. A total of 329 pediatric patients are
currently included. All 329 patients were retrospectively analyzed
for the purpose of the present study.
Definition of Extraintestinal Manifestation and
Anti–tumor Necrosis Factor Outcome
All EIM had to be diagnosed by clinical experts: diagnosis of
skin manifestations was established by a dermatologist, joint affec-
tions by a rheumatologist, eye manifestations by an ophthalmolo-
gist, and PSC by a gastroenterologist. We analyzed the following
EIM: peripheral arthritis, uveitis, PG, EN, aphthous stomatitis, axial
arthropathy, psoriasis, and PSC. Diagnosis of EIM relied on pre-
viously published criteria (7,25,29). We did not consider anemia,
glaucoma, and pancreatic involvement as EIM because it may also
be considered as complication of IBD therapy (25). Evolution of
EIM under anti-TNF treatment was judged according to the phys-
ician’s global assessment, which was based on patient history and
clinical findings. This anti-TNF response was classified into the
following 3 categories: clinical improvement, stable disease course
unaffected by anti-TNF treatment, and clinical worsening.
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Data Collection and Management
Completed patient and physician questionnaires (baseline
and annual follow-up) were sent to the datacenter of the SIBDCS
located at the Institute of Social and Preventive Medicine, Univer-
sity of Lausanne, Switzerland, where data were validated by the
responsible data manager and finally entered into a Microsoft
Access database (Access 2000; Microsoft Switzerland Ltd. Liab.
Co., Wallisellen, Switzerland). Baseline questionnaire at enrollment
and annual follow-up questionnaires included demographic data,
IBD subtype and diagnosis, disease localization according to
international guidelines, prior and current medications, and past
and present EIM. Electronic and written charts of those patients,
who reported past or present EIM, were additionally reviewed by
clinical experts to extract exact appearance of EIM in relation to
IBD diagnosis, EIM subtype, chronological order of appearance of
multiple EIM, and evolution of EIM in response to anti-TNF
treatment. All 329 patients in the PSIBDCS were eligible. For
detailed analysis, only those patients with 1 or more EIM were
included. For a comparison between the pediatric and adult popu-
lation, data from the SIBDCS were used according to a recent study
conducted by Vavricka et al (7).
Statistical Analysis
For all statistical analyses, IBM software SPSS version
23.0.0 (2014 SPSS Science, Inc., Armonk, NY) was used. Metric
data are shown as medians with their total range. Categorical data
are depicted as percentage of the group total. Comparison between
categorical variables was performed by using Chi-square test or
Fisher exact test, if sample size was low (n< 10). A 2-sided P value
of <0.05 was considered statistically significant. The association
between potential predicting factors and positive anti-TNF outcome
was analyzed by means of logistic regression.
RESULTS
Patient Demographics
Of the 329 pediatric patients with IBD included in the study,
173 (52.6%) had CD and 156 (47.4%) had UC/IBD-unclassified
(IBD-U), 148 patients were girls (45.0%). Median age at enrollment
was 14 years (0–17) and median age at IBD diagnosis was 12 years
(0–16). The patients had been experiencing IBD for a median of 3
years (0–16). Patient demographics according to IBD subtype
(including disease localization and received medications) are sum-
marized in Table 1. Of the 329 patients, 55 presented with 1 or more
EIM (16.7%). The characteristics of those patients are depicted in
Table 2.
Frequency and Types of Extraintestinal
Manifestation
Of the 55 patients with at least 1 EIM, 39 patients had CD
(39/55, 70.9%), 12 patients had UC (12/55, 21.8%), and 4 patients
had IBD-U (4/55, 7.3%) as their underlying condition. Of these 55
patients with EIM, 39 (70.9%), 12 (21.8%), 3 (5.5%), and 1 patient
(1.8%) reported 1, 2, 3, and 4 EIM, respectively. At IBD onset,
presence of EIM was more frequent than that in the adult population
(28/329, 8.5% vs 62/1249, 5.0%, P¼ 0.014). EIM were more
frequently observed in patients with CD (39/173, 22.5%) when
compared to patients with UC/IBD-U (16/156, 10.3%, P¼ 0.003).
The most prevalent EIM were peripheral arthritis (26/329, 7.9%)
and aphthous stomatitis (24/329, 7.3%), followed by uveitis (6/329,
1.8%), EN (5/329, 1.5%), axial arthropathy (5/329, 1.5%), psoriasis
(4/329, 1.2%), PSC (4/329, 1.2%), and PG (2/329, 0.6%). Peripheral
arthritis, axial arthropathy, and EN were less frequently encoun-
tered among pediatric patients with IBD compared to adult patients
(7.9% vs 20.5%, P< 0.001; 1.5% vs 4.8%, P¼ 0.008; and 1.5% vs
3.7%, P¼ 0.048). Frequency of other EIM was comparable
between the 2 populations. For a detailed overview see Figure 1.
Although 27.6% of all EIM (21/76) appeared before the diagnosis of
IBD, the majority of EIM appeared once IBD diagnosis was
established (42/76, 55.3%). The remaining proportion of EIM
(12/76, 15.8%) was first observed at the time of establishment of
IBD diagnosis. Data from 1 EIM were missing. So, at the time of
IBD diagnosis, 28 of the 55 patients presented with a total of 33 EIM
(observed before or at the time of IBD diagnosis); aphthous
stomatitis and peripheral arthritis were again the most frequently
observed EIM (15/28, 53.6% and 10/28, 35.7%, respectively). For a
synopsis over the phenotypic features at IBD diagnosis see Supple-
mental Digital Content 1, Table 1 (http://links.lww.com/MPG/
A827). Details about frequency and type of EIM according to
IBD subtype are shown in Table 2.
Distribution of Different Extraintestinal
Manifestation According to Their
Chronological Appearance
Aphthous stomatitis was the most prevalent EIM (21/55,
38.2%), which appeared as first EIM (n¼ 55), followed by per-
ipheral arthritis (19/55, 34.5%) and uveitis (4/55, 7.3%). If the
patient was diagnosed with a second EIM (n¼ 16), peripheral
arthritis (5/16, 31.3%), EN (3/16, 18.8%), aphthous stomatitis (2/
16, 12.5%), and axial arthropathy (2/16, 12.5%) were most frequent.
In those patients presenting with a third EIM (n¼ 4), occurrence of
the following EIM were reported: peripheral arthritis (1/4, 25.0%),
uveitis (1/4, 25.0%), aphthous stomatitis (1/4, 25.0%), and psoriasis
(1/4, 25.0%). Median time between IBD diagnosis and occurrence
of first EIM was 1 month (range –37.5–149.0). Figure 2 illustrates
the chronological order of appearance of each individual EIM in
relation to the time of IBD diagnosis (in months). Peripheral
arthritis appeared before IBD diagnosis in 28.0% (7/25, exact
appearance in 1 case unknown), uveitis in 16.7% (1/6), EN in
20% (1/5), axial arthropathy in 40.0% (2/5), and aphthous stomatitis
in 29.2% (7/24). All cases of psoriasis (4/4, 100%) and PG (2/2,
100%) appeared after IBD diagnosis were established. In addition,
peripheral arthritis (64.0% vs 28.0%, P¼ 0.011) and uveitis (83.3%
vs 16.7%, P¼ 0.021) were significantly more likely to appear after
diagnosis of IBD than before establishment of IBD diagnosis.
Median lag of time of appearance before IBD diagnosis in the
group of patients in whom EIM preceded IBD diagnosis was 5.0
months (range 37.5 to 0.4).
Type of Anti–tumor Necrosis Factor Treatment
and Treated Extraintestinal Manifestation
Anti-TNF therapy was initiated in 31 of the 55 patients with
EIM (56.4%). Most of them were treated with a single anti-TNF agent
(23/31, 74.2%), whereas 5 patients were treated with 2 and 3 patients
with 3 different anti-TNF agents (5/31, 16.1% and 3/31, 9.7%,
respectively). So, a total of 42 treatment courses were initiated. In
78.6% (33/42), anti-TNF treatment was started for the purpose of
treating underlying IBD activity. In 3 cases (3/42, 7.1%), anti-TNF
was solely initiated for the purpose of treating EIM; infliximab was
started for peripheral arthritis (n¼ 1) and axial arthropathy (n¼ 1);
and adalimumab was initiated for peripheral arthritis (n¼ 1). In 5
cases (5/42, 11.9%), anti-TNF was started for the purpose of treating
both intestinal disease activity and EIM. In 1 case, exact indication for
Greuter et al JPGN  Volume 65, Number 2, August 2017
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anti-TNF treatment was not known. IBD patients presenting with
EIM were more likely to be treated with anti-TNF compared to those
without EIM (31/55, 56.4% vs 96/274, 35.0%, P¼ 0.003). The most
frequently treated EIM were peripheral arthritis (16/42, 38.1%) and
aphthous stomatitis (13/42, 31.0%), followed by axial arthropathy,
uveitis, and EN. For details see Table 3. Under anti-TNF treatment, 23
EIM appeared in 19 of the 31 treated patients (19/31, 61.3%). Among
those 23 EIM, peripheral arthritis (6 cases) and aphthous stomatitis (5
cases) were the most frequently reported. Three cases of psoriasis
occurred under anti-TNF therapy, which can be considered as anti-
TNF-induced psoriasiform skin lesions. Further reported EIM, which
appeared under anti-TNF, were: uveitis (2 cases), PG (1 case), EN (2
cases), and axial arthropathy (1 case). In remaining 3 cases, the exact
EIM subtype was unknown.
Clinical Evolution of Extraintestinal
Manifestation Under Anti–tumor Necrosis
Factor Treatment
Data on clinical outcome of anti-TNF treatment were
available for 37 of the 53 treated EIM (69.8%). In the majority,
EIM showed improvement (17/37, 45.9%) or stable disease
course (13/37, 35.1%), whereas clinical worsening was observed
in only 7 cases (7/37, 18.9%). Peripheral arthritis and uveitis
showed good clinical response rates to anti-TNF (61.5% and
66.7%, respectively), whereas those of PG, axial arthropathy,
aphthous stomatitis, and EN were 50% (50.0%, 50.0%, 33.3%,
and 33.3%, respectively, Table 3). In a multivariate regression
model adjusted for age and sex, appearance of EIM before IBD
diagnosis was the only independent predictor for positive anti-
TNF outcome (odds ratio 9.70, 95% confidence interval 1.04–
90.04, P¼ 0.046). Details about the multivariate analysis can be
found in the Supplemental Digital Content 2, Table 2 (http://
links.lww.com/MPG/A828).
DISCUSSION
In this analysis of the PSIBDCS, we report on frequency and
chronological order of appearance of EIM, the use of anti-TNF
agents, and the disease course under such therapy. EIM are
common in pediatric patients with IBD and can appear in nearly
30% before IBD diagnosis is established. Anti-TNF are used
frequently in those patients, although they are started for the
TABLE 1. Patient demographics of the pediatric cohort
CD patients UC/IBD-U patients All IBD patients
Number of patients 173 (52.6) 156 (47.4) 329 (100.0)
Sex
Male 104 (60.1) 77 (49.4) 181 (55.0)
Female 69 (39.9) 79 (50.6) 148 (45.0)
Age at diagnosis in years 12, 10–14 11, 7–14 12, 9–14
(median, IQR, range) 0–16 0–16 0–16
Age at enrollment, y 14, 12–15 13, 11–15 14, 11–15
(median, IQR, range) 0–17 0–17 0–17
Age at latest follow-up, y 16, 14–17 16, 13–17 16, 13–17
(median, IQR, range) 0–18 0–18 0–18
Disease duration, y 3, 2–5 3, 1–6 3, 2–5
(median, IQR, range) 0–15 0–16 0–16
Diagnostic delay, mo 4.1, 2.0–8.1 3.0, 1.0–6.1 3.1, 2.0–7.1
(median, IQR, range) 0–83.2 0–59.9 0–83.2
Initial disease location (CD)
L1 23 (13.3) –
L2 22 (12.7) –
L3 119 (68.8) –
L4 only 3 (1.7) –
Unknown/unclear 6 (3.5) –
Initial disease location (UC)
E1 – 13 (8.3)
E2 – 28 (18.0)
E3/E4 – 104 (66.7)
Unknown/unclear – 11 (7.0)
Fistulas
Perianal fistula 24 (13.9) –
Other fistula 12 (6.9) –
Stenosis
Any stenosis 22 (12.7) –
Medication ever received
5-ASA 84 (48.6) 149 (95.5) 233 (70.8)
Antibiotics 64 (37.0) 46 (29.5) 110 (33.4)
Steroids 140 (80.9) 117 (75.0) 257 (78.1)
Immunomodulators 155 (89.6) 101 (64.7) 256 (77.8)
Anti-TNF 87 (50.3) 40 (25.6) 127 (38.6)
CD ¼ Crohn disease; IBD-U ¼ inflammatory bowel disease-unclassified; TNF ¼ tumor necrosis factor; UC ¼ ulcerative colitis.
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purpose of treating EIM in only a minority. Type of EIM may affect
anti-TNF outcome. Best response rates were seen for peripheral
arthritis and uveitis.
EIM were frequently encountered in pediatric IBD, the
prevalence of 16.7% is comparable to prior data from Guariso
et al (26). Prevalence is, however, considerably lower compared to
the studies conducted by Dotson et al (29) and Jose et al (25), which
is mainly due to our more stringent definition of EIM, because we
did not include nonspecific arthralgia or other nonspecific EIM such
as anemia, hepatitis, pancreatitis, or osteoporosis. In accordance to
the findings of Guariso et al (26), presence of EIM at IBD onset was
more frequent in the PSIBDCS compared to the adult population
(8.5% vs 5%), although difference was considerably smaller (14.3%
vs 7.3% in the study of Guariso). Our numbers fit well within the
TABLE 2. Demographics and frequency and type of extraintestinal manifestation according to inflammatory bowel disease subtype
All, n¼ 55 (%) UC, n¼ 12 (%) CD, n¼ 39 (%) IBD-U n¼ 4 (%)
Sex
Male 34 (61.8) 6 (50.0) 26 (66.7) 2 (50.0)
Female 21 (38.2) 6 (50.0) 13 (33.3) 2 (50.0)
Age at IBD diagnosis in years 11.3 (0.8–15.7) 9.5 (2.5–15.5) 11.5 (0.8–15.4) 14.0 (12.4–15.7)
Number of EIM
1 39 (70.9) 6 (50.0) 29 (74.4) 4 (100.0)
2 12 (21.8) 6 (50.0) 6 (15.4) 0 (0.0)
3 3 (5.5) 0 (0.0) 3 (7.7) 0 (0.0)
4 1 (1.8) 0 (0.0) 1 (2.6) 0 (0.0)
Age at first EIM in years 12.8 (3.1–17.4) 11.5 (3.8–15.4) 13.1 (3.1–17.4) 13.0 (9.3–14.9)
Time from IBD to first EIM in months 1.0 (–37.5–149.0) 5.0 (–26.0–149.0) 1.5 (–28.0–102.0) –18.0 (–37.4–1.0)
Type of EIM
Arthritis 26 (47.3) 6 (50.0) 19 (48.7) 1 (25.0)
Uveitis 6 (10.9) 0 (0.0) 5 (12.8) 1 (25.0)
PG 2 (3.6) 1 (8.3) 1 (2.6) 0 (0.0)
EN 5 (9.1) 1 (8.3) 4 (10.3) 0 (0.0)
Stomatitis 24 (43.6) 5 (41.7) 18 (46.2) 1 (25.0)
AS 5 (9.1) 2 (16.7) 3 (7.7) 0 (0.0)
PSC 4 (7.3) 3 (25.0) 0 (0.0) 1 (25.0)
Psoriasis 4 (7.3) 0 (0.0) 4 (10.3) 0 (0.0)
Occurrence of EIM n¼ 76 n¼ 18 n¼ 54 n¼ 4
Before 21 (27.6) 4 (22.2) 14 (25.9) 3 (75.0)
Concomitant 12 (15.8) 3 (16.7) 9 (16.7) 0 (0.0)
After 42 (55.3) 11 (61.1) 30 (55.6) 1 (25.0)
Unknown 1 (1.3) 0 (0.0) 1 (1.9) 0 (0.0)
AS ¼ axial arthropathy; CD ¼ Crohn disease; EIM ¼ extraintestinal manifestations; EN¼ erythema nodosum; IBD-U ¼ inflammatory bowel disease-
unclassified; PG¼ pyoderma gangrenosum; PSC ¼ primary sclerosing cholangitis; UC ¼ ulcerative colitis.
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FIGURE 1. Frequency of extraintestinal manifestation (EIM) subtype
among those patients presenting with EIM according to inflammatory
bowel disease (IBD) cohort study (adult vs pediatric). EN ¼ erythema
nodosum; PG ¼ pyoderma gangrenosum; PIBDCS ¼ Pediatric Swiss
IBD Cohort Study; PSC ¼ primary sclerosing cholangitis; SIBDCS ¼
Swiss IBD Cohort Study.
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FIGURE 2. Chronological order of appearance of EIM in relation to the
time of IBD diagnosis. Data are presented as horizontal boxplots. The
box comprises the 25th and 75th percentile; the vertical line in the box
corresponds to the median. AS ¼ axial arthropathy; EIM ¼ extrain-
testinal manifestation; EN ¼ erythema nodosum; IBD ¼ inflammatory
bowel disease; PG ¼ pyoderma gangrenosum; PSC ¼ primary scler-
osing cholangitis.
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range of 6% to 47% EIM prevalence typically reported (2,4–
6,13,30). Our finding that EIM were more frequently observed
in CD compared with UC patients is consistent with prior studies
from adult IBD cohorts (7,8,13). Moreover, the order of frequency
is consistent throughout the adult EIM literature and our data are in
agreement with published observations: musculoskeletal symptoms
(such as peripheral arthritis) are followed by stomatitis, ophthal-
mological problems (such as uveitis), and skin changes (8,25).
Although the proportion of patients presenting with arthritis is
higher among adult patients, order of frequency of EIM did not
show a difference between the adult and pediatric patients with
IBD. EIM were more likely to appear after IBD diagnosis compared
to before. Nonetheless, a non-negligible proportion (up to 30%) of
EIM appeared before IBD diagnosis was established. Axial arthro-
pathy appeared before IBD diagnosis in an even higher proportion.
Both findings are consistent with data from adult cohorts (7). So,
clinicians should be aware of those EIM manifesting before intes-
tinal symptoms to decrease the diagnostic delay. Our group has
recently shown that such diagnostic delay is a concern (31) and that
a delayed diagnosis is associated with a complicated disease course
in patients with CD (32). Appearance of>1 EIM was observed only
infrequently. Thus, the fact that 1 EIM seems to increase the
susceptibility of developing other EIM does not seem to be true
for pediatric patients (33) or latency between first and second EIM
may have been too long to allow detection in children. Taken
together, our data suggest that epidemiology and presentation of
EIM is quite similar in the pediatric and the adult population,
suggesting similar disease mechanisms.
Anti-TNF were frequently used in pediatric patients with
EIM. Those agents were, however, specifically initiated for treating
EIM in only a minority. So, clinical practice seems to be in
accordance to current guidelines, which recommend to treat under-
lying IBD activity rather than EIM themselves. Nonetheless,
patients with EIM were significantly more often treated with
anti-TNF than those without EIM. The latter may be explained
by prior findings from Vavricka et al (8) who showed that active
disease is an independent risk factor for EIM in both UC and CD.
Upon anti-TNF treatment, EIM showed overall response rates of
nearly 50%, which depended on the underlying EIM with the best
rates for peripheral arthritis and uveitis. Although direct compari-
sons are not possible, higher response rates to anti-TNF treatment
were described in the adult population (71.8%) (34). New onset of
EIM under anti-TNF treatment also has been encountered in our
study. Diagnosis of psoriasis was established in 3 of the 31 anti–
TNF-treated patients, which can be interpreted retrospectively as
anti–TNF-induced psoriasiform skin lesion. Prevalence seems to be
in accordance to that reported in the literature (35).
Our study has several strengths and some limitations as well.
So far, it is one of the largest analyses of collected data evaluating
frequency and occurrence of EIM in the pediatric IBD population.
Furthermore, a detailed chart review revealed information about
chronological appearance of EIM according to EIM subtype, the use
of anti-TNF treatment and clinical response to such a therapy. The
combination of physician- and patient-based questionnaire may
have prevented the underreporting of EIM in our study population.
We, however, used an uncontrolled, noninterventional study design,
which limits interpretation of anti-TNF treatment outcome. With
annual follow-up visits, important details occurring during this
period of time may have been missed. This potential recall bias
has, however, been limited by the combination of physician- and
patient-based questionnaires. Given the fact that the Pediatric Swiss
IBD cohort is not strictly population based, a selection bias may be
present. For instance, patients included by private practices and
community hospitals were underrepresented compared with those
patients included by university hospitals (30.9% of the patients
presenting with EIM were recruited in private practices or com-
munity hospitals, whereas 69.1% were recruited by physicians
working in a university hospital). A clear limitation of our analysis
is that—at the time of data analysis—we did not clearly differen-
tiate between psoriasis and psoriasiform anti–TNF-associated skin
lesions, which is an increasingly reported phenomenon (35). With 4
cases, prevalence of psoriasis was, however, extremely low, and 3
out of 4 cases can be retrospectively considered as anti-TNF
induced as they presented under anti-TNF treatment for the first
time. Because of the retrospective nature of the study, a non-
negligible proportion of patients received concomitant immuno-
modulators and/or steroids in addition to anti-TNF, which may have
led to an overestimation of anti-TNF response rates.
In summary, in a cohort of pediatric patients with IBD, EIM
were frequently encountered. In up to 30% of patients, EIM
appeared before IBD was diagnosed. Knowledge of these findings
may result in increased awareness of underlying IBD, thereby
decreasing potential diagnostic delay. Anti-TNF for the treatment
of certain EIM is effective, although a substantial proportion of new
EIM may present despite ongoing anti-TNF therapy. Randomized
controlled trials are, however, needed in the pediatric IBD
population.
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